Clear, engaging, and practical updates on clinical psychiatry.
Earn CME for listening to the podcast with a Podcast CME Subscription.
Listen for free here or using Apple Podcasts and Spotify.
For years, we have dreaded seeing our patients develop antipsychotic-induced tardive dyskinesia because there was little we could do about these symptoms. Thankfully, we now have new treatments that produce noticeable improvements in tardive dyskinesia.
This podcast addresses the best treatments for various substance use disorders in pregnant women, outlines which substances have the highest potential for producing negative pregnancy outcomes.
Experts tackle various research topics in the field of child psychiatry, from the risk of stimulant-induced psychosis in youth with ADHD to the efficacy and safety of SSRIs and SNRIs for young people with psychiatric disorders.
On average, people with schizophrenia die 20–25 years sooner than those without schizophrenia. How can we spot metabolic side effects early in our patients, and what should we be looking for exactly?
Several studies are discussed in this podcast, including one that suggests modest clinical utility for short-term use of melatonin in children and adolescents struggling with sleep-onset insomnia.
Drew Ramsey, MD, talks about new research behind nutritional psychiatry. At the end there’s going to be a test. That’s right – a real CME test so you can start earning credits directly from the podcast.
How does schizophrenia differ between men and women? And are there adjunctive treatments that can improve outcomes for female patients with schizophrenia?
Aducanumab (Aduhelm) just got FDA approval in dementia, but many experts think it should not have passed the finish line. We interviewed Peter Whitehouse, professor of neurology at Case Western Reserve University and author of American Dementia, on what went wrong.